Understanding side effects of combined cancer treatments
Attribution of Toxicities Due to Radiotherapy and Immuno-Biological Therapies - Registry
This study is trying to see how often severe side effects happen when people with cancer receive both molecular therapies and radiotherapy together compared to when they get them separately.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3600 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre hospitalier de l'Université de Montréal (CHUM) Academic / other |
| Drugs / interventions | Radiation, immunotherapy |
| Locations | 1 site (Montreal, Quebec) |
| Trial ID | NCT04115267 on ClinicalTrials.gov |
What this trial studies
This observational registry aims to gather data from patients receiving both molecular therapies and radiotherapy for cancer. It focuses on collecting information about diagnoses, treatment doses, types of therapies, and reported side effects. By analyzing this data, the study seeks to determine the prevalence of severe side effects when these treatments are used together compared to when they are used separately. Patient-reported outcomes regarding their quality of life and perceived side effects will also be included in the analysis.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years old with a histological diagnosis of primary cancer who are receiving molecular therapy and are indicated for radiotherapy.
Not a fit: Patients who refuse or are unable to receive radiotherapy will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management of side effects for cancer patients undergoing combined treatments.
How similar studies have performed: While there have been studies on the effects of individual treatments, this registry approach to understanding the combined effects of molecular therapies and radiotherapy is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Consent to be part of the AtTRIBut registry * Prior histological diagnosis of primary cancer. * If the patient has metastatic disease, there must be radiological or pathological evidence of metastasis * Age\> 18 years * Receiving a molecular therapy * Indicated to receive radiotherapy * Radiation therapy can be administered using 3D conventional, IMRT or SBRT techniques. Exclusion Criteria: • Refusal or inability to receive radiotherapy
Where this trial is running
Montreal, Quebec
- Centre Hospitalier de l'Université de Montréal — Montreal, Quebec, Canada (Recruiting)
Study contacts
- Principal investigator: Philip Wong, MD — Chum
- Study coordinator: Mom Phat, RN
- Email: mom.phat.chum@ssss.gouv.qc.ca
- Phone: 1-514-8908000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.